LTRN Lantern Pharma Inc.
$1.71▼ -2.84%
Healthcare
Other
After hours
$1.71▲ +0.00%
Sep 11, 7:30 PM ET
Volume 109.8K
Avg Volume (10D) 167.1K
Key Metrics & Fundamentals
Market Cap
$21.86M
P/E Ratio
–
Div Yield
–%
52W Range
1.11 - 4.70
% vs 50 MA
-35.01%
% vs 200 MA
-40.96%
RSI-14
20.7
MACD Histogram
-0.0100
Beta (1Y vs SPY)
2.82
Free Cash Flow
-$2.94M
Gross Rev
$0
Gross Profit
$0
EBITDA
-$1.38M
COGS
–
Operating Exp
$3.51M
Operating Income
-$3.51M
EBIT
-$3.51M
Pretax Income
-$7.07M
Net Income
-$7.07M
EPS (Diluted)
-0.57
Price & Volume History
Loading chart…
Recent News
New to The Street Broadcasts at 6:30 PM ET Across Bloomberg U.S., Latin America and MENA, Featuring Lantern Pharma (NASDAQ:LTRN), SafeSpace Global (OTCID:SSGC) and FreeCast (NASDAQ:CAST)
ACCESS Newswire · Sep 5, 2026 2:50 PM
Lantern Pharma (LTRN) Q2 2026 Earnings Call Transcript
Motley Fool · Aug 21, 2026 12:28 PM
Lantern Pharma Inc (LTRN) (Q2 2026) Earnings Call Highlights: AI-Driven Pipeline Advances Amid ...
GuruFocus.com · Aug 20, 2026 1:03 AM
Lantern Pharma Inc. Q2 2026 Earnings Call Summary
Moby · Aug 14, 2026 4:51 PM
Lantern Pharma Reports Second Quarter 2026 Financial Results and Provides Business Update
Business Wire · Aug 14, 2026 11:30 AM
Lantern Pharma to Report Second Quarter 2026 Operating & Financial Results on August 14th, 2026 at 9:00 a.m. ET
Business Wire · Aug 7, 2026 12:00 PM
Lantern Pharma (Nasdaq: LTRN) Establishes Open-Medicine AI as a Separate Company to Commercialize and Expand Its Multi-Agent AI Co-Scientist Platform for the Transformation of Medicine
Business Wire · Aug 3, 2026 11:30 AM
Lantern Pharma Says Zirdafulven Phase 1b/2 Trial in Bladder Cancer Cleared by European Medicines Agency
MT Newswires · Jul 28, 2026 12:35 PM
Lantern Pharma to Advance EMA-Cleared Phase 1b/2 Trial of LP-184 (Zirdafulven) in Biomarker-Selected Advanced Bladder Cancer
Business Wire · Jul 28, 2026 11:45 AM
Lantern Pharma Receives US Patent Allowance for Cancer Drug LP-184
MT Newswires · Jul 23, 2026 12:57 PM
Financial Overview - Income Statement
Quarterly
No financial data available. Click Refresh on the ticker to load latest fundamentals.
See LTRN's money flow as a full page
Social Sentiment
Avg +0.63 · 3 posts
NewsDiscussion($LTRN) Does It Make Sense for Lantern to Announce withZeta Before BIO2026?
r/investing · Jun 17, 2026
The author suggests a strategic update before BIO2026 is logical, indicating optimism about Lantern's future.
positive
+0.70
DDNewsDiscussionWhy RADR Could Be Lantern Pharma's Most Undervalued Asset
r/investing · Jun 16, 2026
The discussion centers around Lantern Pharma and its LP-300 program.
positive
+0.60
NewsDiscussionDDLantern Pharma ($LTRN): Why Is the Market Valuing an AI Oncology Platform at Only $50M?
r/investing · Jun 13, 2026
Focus on platform value and continued investment in key programs indicates optimism.
positive
+0.60
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.